Abstract library

13 results for "Grillo".
#2803 Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study
Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous, serum chromogranin A (CgA) has a 60-100% of sensitivity and 68-100% of specificity with a cutoff value of 108 ng/mL as a marker for diagnosis of NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Matias Munoz Medel
#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile
Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Diego Carrillo
#2841 Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) WHO classification, using strict cut-offs, should reflect their biological features. In real world, strict cut-offs not adequately segregate prognostic groups, in particular on metastasis (M).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Massimo Milione
#129 Grade according to Ki-67 or mitotic count in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) are uncommon tumors with a reported incidence of 2.5-5 per 100000 population. The recent classification system of NETs proposed by the European Neuroendocrine Tumor Society (ENETS) uses both Ki-67 labelling index and mitotic index to assign grade (low, intermediate, high). It has been adopted into routine practice but there is limited data on the relationship between these indices and their effect on classification.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#160 The role of T-type calcium channels in medullary thyroid carcinoma (MTC): T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a human MTC cell line
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5-10% of thyroid cancers. In the case of tumors limited to the thyroid gland, the prognosis is generally favorable, whereas 5-year survival averages only 40% in patients with metastatic disease. In these patients, conventional chemotherapy only occasionally leads to a complete response and partial responses are observed in less than 30% of the cases. Therefore, intense efforts are currently directed toward the identification of new druggable targets for the treatment of this devastating disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Rosario Pivonello
#432 Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation with Follow-up in 50 Patients
Introduction: In the last decade, GEP-NET nomenclature has been twice reviewed. The 2000 WHO classification had poor prognostic power in well-differentiated (WD) neoplasms which led to the introduction of two new important parameters: grade and stage, by ENETS; the former became part of the new 2010 WHO classification.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Diego Ferone
#584 KI-67 HETEROGENEITY IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMORS
Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETs/WHO) has proved reliable for prognostic stratification, however concerns exist on Ki67 heterogeneity.
Conference:
Category: Basic
Presenting Author: Dr Federica Grillo
#587 First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus.
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference:
Category: Basic
Presenting Author: MD Manuela Albertelli
#752 First In Vitro Study of Human Gastroenteropancreatic Neuroendocrine Tumors: Comparative Effect of Octreotide, Pasireotide and Everolimus
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Diego Ferone
#836 Grade Increases In Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor
Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETS/WHO) has proved reliable for prognostic stratification of gastroenteropancreatic tumors (GEP). Although anecdotes have been published, no single study has evaluated whether grade changes between primary site and metastases.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Prof Federica Grillo